Predicting antimicrobial resistance in invasive pneumococcal infections

被引:159
作者
Vanderkooi, OG
Low, DE
Green, K
Powis, JE
McGeer, A
机构
[1] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[2] Toronto Med Labs, Shared Dept Microbiol, Toronto, ON, Canada
[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
关键词
D O I
10.1086/429242
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The prevalence of multiantimicrobial resistance among Streptococcus pneumoniae continues to increase worldwide. In patients presenting with infection possibly due to pneumococci, recognition of risk factors that would identify those likely to have an antibiotic-resistant isolate might assist clinicians in choosing the most appropriate empirical therapy. Methods. A prospective cohort study of invasive pneumococcal infection was conducted in Toronto, Canada. Risk factors for antimicrobial resistance were evaluated by means of univariate and multivariate modeling. Results. A total of 3339 patients with invasive pneumococcal infection were identified between 1995 and 2002. Multivariate modeling revealed that risk factors for infection with penicillin-resistant as opposed to penicillin-susceptible pneumococci were year of infection ( odds ratio [OR], 1.28; P < .001), absence of chronic organ system disease ( OR, 1.72; P = .03), and previous use of penicillin ( OR, 2.47; P = .006), trimethoprim-sulfamethoxazole (TMP-SMX; OR, 5.97; P < .001), and azithromycin (OR, 2.78; P = .05). Infection with TMP-SMX-resistant pneumococci was associated with absence of chronic organ system disease (OR, 1.64; P = .001) and with previous use of penicillin (OR, 1.71; P = .03), TMP-SMX (OR, 4.73; P < .001), and azithromycin (OR, 3.49; P = .001). Infection with macrolide- resistant isolates was associated with previous use of penicillin ( OR, 1.77; P = .03) TMX (OR, 2.07; P = .04), clarithromycin (OR, 3.93; P < .001), and azithromycin (OR, 9.93; P < .001). Infection with fluoroquinolone-resistant pneumococci was associated with previous use of fluoroquinolones (OR, 12.1; P < .001), current residence in a nursing home (OR, 12.9; P < .001), and nosocomial acquisition of pneumococcal infection (OR, 9.94; P = .003). Conclusions. Knowledge of antimicrobial use during the 3 months before infection is crucial for determining appropriate therapy for a patient presenting to the hospital with an illness for which S. pneumoniae is a possible cause. Nosocomial acquisition and nursing home acquisition are significant risk factors for infection with fluoroquinoloneresistant pneumococci.
引用
收藏
页码:1288 / 1297
页数:10
相关论文
共 43 条
[1]   Global antibiotic resistance in Streptococcus pneumoniae [J].
Adam, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :1-5
[2]  
[Anonymous], [No title captured]
[3]   The pneumococcus at the millennium: Not down, not out [J].
Austrian, R .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S338-S341
[4]   Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: Findings of a French survey [J].
Bedos, JP ;
Chevret, S ;
Chastang, C ;
Geslin, P ;
Regnier, B .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (01) :63-72
[5]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[6]   Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study [J].
ClavoSanchez, AJ ;
GironGonzalez, JA ;
LopezPrieto, D ;
CanuetoQuintero, J ;
SanchezPorto, A ;
VergaraCampos, A ;
MarinCasanova, P ;
CordobaDona, JA .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1052-1059
[7]  
DANEMAN N, 2004, 44 INT C ANT AG CHEM
[8]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750
[9]  
de Galan BE, 1999, J HOSP INFECT, V42, P185, DOI 10.1053/jhin.1999.0580
[10]   Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997 [J].
Feikin, DR ;
Schuchat, A ;
Kolczak, M ;
Barrett, NL ;
Harrison, LH ;
Lefkowitz, L ;
McGreer, A ;
Farley, MM ;
Vugia, DJ ;
Lexau, C ;
Stefonek, KR ;
Patterson, JE ;
Jorgensen, JH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (02) :223-229